Abstract
Objective Previous studies have demonstrated quality concerns with misoprostol. Mifepristone, however, has not been extensively assessed for quality. Between 2020 and 2021, Concept Foundation and the International Planned Parenthood Federation conducted a study to determine the quality of these medical abortion drugs in low– and middle-income countries (LMIC).
Methods Collection of batch samples of misoprostol and mifepristone was carried out by trained sampling agents in selected LMIC. Single drug packs and combipacks were sampled. A World Health Organization prequalified laboratory conducted testing method verifications and subsequent sample analysis. Tests included identification, assay, related substances, and content uniformity for misoprostol, and identification, assay, related substances, and dissolution for mifepristone.
Results Samples were collected from Burkina Faso, Cambodia, Democratic Republic of Congo, India, Kyrgyzstan, Moldova, Nepal, Nigeria, Pakistan, Uganda and Vietnam. Sixty-four pooled batch samples were tested, consisting of 31 combipacks, 26 misoprostol-only and 7 mifepristone-only products. Overall, 54.7% of samples were non-compliant with one or more of the specifications, representing 51.6% of combipack products, 57.1% of misoprostol tablets analyzed and 23.7% of mifepristone tablets. One falsified misoprostol-only product was found.
Conclusion This study confirms that a significant problem still exists in relation to the quality of medical abortion drugs in low– and middle-income countries. For misoprostol, our findings suggest that historical concerns around primary packaging may have been largely resolved but that manufacturing processes for both finished product and active pharmaceutical ingredient need to be improved. This study also provides evidence of mifepristone quality issues.
Competing Interest Statement
At the time of the study, Concept Foundation had a sublicensing agreement with Sun Pharmaceutical Industries, the manufacturer of Medabon combipack, samples of which were included in our sample. Testing was conducted by an independent laboratory and Concept Foundation staff were not involved in the identification of the samples during testing. Authors not employed by Concept Foundation declare that they have no conflicts of interest.
Funding Statement
This work was supported by the UNDP‐UNFPA‐UNICEF‐WHO‐World Bank Special Program of Research, Development and Research Training in Human Reproduction (HRP), a cosponsored program executed by the World Health Organization (WHO). Disclaimer: The views expressed in this article are those of the authors and do not necessarily represent the views of, and should not be attributed to the World Health Organization.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical reasons.
List of abbreviations
- API
- Active pharmaceutical ingredient
- CRS
- Chemical reference standard
- EDQM
- European Directorate for the Quality of Medicines
- EML
- Essential Medicines List
- FDA
- Food and Drug Authority
- FPP
- Finished pharmaceutical product
- GMP
- Good Manufacturing Practice
- HCI
- Health Concepts International
- HPLC
- High-performance liquid chromatography
- ICH
- International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use
- InphA
- Institute for Pharmaceutical and Applied Analytics
- IPPF
- International Planned Parenthood Federation
- ISF
- Incidents and Substandard / Falsified Medical Products
- LMIC
- Lower– and middle-income countries
- LOQ
- Limit of quantitation
- OOS
- Out of specification
- Ph. Int.
- International Pharmacopoeia
- PQP
- Prequalification Program
- QA
- Quality assurance
- SCF
- Sample collection form
- SMO
- Social marketing organization
- SOP
- Standard operating procedure
- SRA
- Stringent regulatory authority
- UK
- United Kingdom
- UN
- United Nations
- USAID
- United States Agency for International Development
- USD
- United States Dollar
- USP
- United States Pharmacopoeia
- WHO
- World Health Organization
- WLA
- WHO-Listed Authority
